Bicara Therapeutics Inc. $BCAX Shares Purchased by Siren L.L.C.

Siren L.L.C. boosted its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 11.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,802,970 shares of the company’s stock after purchasing an additional 586,001 shares during the quarter. Bicara Therapeutics comprises 3.2% of Siren L.L.C.’s portfolio, making the stock its 7th largest holding. Siren L.L.C. owned approximately 0.09% of Bicara Therapeutics worth $115,421,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BCAX. Vestal Point Capital LP raised its position in shares of Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after purchasing an additional 100,000 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Bicara Therapeutics during the 4th quarter worth about $44,484,000. Vanguard Group Inc. increased its stake in Bicara Therapeutics by 9.8% during the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after acquiring an additional 195,667 shares during the period. Finally, State Street Corp raised its stake in shares of Bicara Therapeutics by 179.5% in the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares in the last quarter.

Insider Buying and Selling at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 28,214 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the transaction, the chief operating officer owned 182,177 shares in the company, valued at approximately $5,279,489.46. This represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total transaction of $807,800.00. Following the sale, the chief financial officer directly owned 129,855 shares in the company, valued at $3,746,316.75. This trade represents a 17.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 93,950 shares of company stock worth $2,492,515. Company insiders own 13.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BCAX shares. Wells Fargo & Company raised their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. HC Wainwright upped their price objective on Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Guggenheim started coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 target price on the stock. Finally, Citizens Jmp restated a “market outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Stock Down 0.8%

Shares of BCAX stock opened at $27.73 on Friday. The firm has a fifty day moving average of $24.42 and a 200-day moving average of $20.81. Bicara Therapeutics Inc. has a 12-month low of $9.57 and a 12-month high of $30.99. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.97 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, equities analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.